Hexarelin oral: Frequently asked questions

Rinse your mouth immediately with water and expectorate. Do not swallow. The amount of peptide absorbed through accidental oral contact is negligible (micrograms at most), but the bitter taste will persist for 10–20 minutes. Gastric enzymes will degrade any swallowed peptide within minutes, rendering it inactive. The taste itself is not a toxicity concern; it simply indicates you've contacted the peptide directly. Review your reconstitution technique: accidental taste exposure usually results from aerosolized particles escaping the vial when the needle is withdrawn, or from touching your face with contaminated gloves. Use a laminar flow hood if available, or work in a clean, draft-free area away from your face.

Use injectable hexarelin exclusively. Oral administration cannot produce the Cmax required to saturate GHS-R1a receptors and trigger maximal secretagogue response. A 100 mcg/kg subcutaneous dose in rats delivers peak GH concentrations within 30 minutes, allowing precise measurement of pulse amplitude via serial blood sampling at 15-minute intervals. Oral dosing produces a flatter, delayed curve that underestimates true secretagogue potency and introduces timing variability that confounds endpoint measurement.

Oral hexarelin may reduce procedural stress and improve model welfare compared to daily subcutaneous injections, but you must account for the 5–8× dose penalty and accept lower GH output. If your endpoint is chronic GHS-R1a modulation rather than peak GH secretion. Such as appetite regulation, reward-seeking behavior, or neuroprotective signaling. Oral administration delivers sustained low-level receptor engagement without the peak-trough oscillations of injection. Dose at 500–800 mcg orally (rodent-equivalent scaling) and validate receptor occupancy via secondary markers rather than relying on plasma GH alone.

Switch to subcutaneous administration immediately. Oral hexarelin bioavailability varies 30–50% based on gastric pH (fasted versus fed), hepatic cytochrome P450 polymorphism, and intestinal transit time. These variables introduce noise that no amount of dose titration can eliminate. Injectable formulations bypass the GI tract and liver entirely, producing dose-proportional plasma exposure with minimal inter-subject variability. If your study has already begun and switching routes mid-protocol isn't feasible, standardize fasting intervals (administer oral doses after a minimum 4-hour fast) and collect blood samples at consistent post-dose intervals to reduce within-subject variability.

Weak or absent bitterness may indicate degraded peptide, low purity, or contamination with sweet-tasting excipients like mannitol. Verify storage conditions first: lyophilized hexarelin exposed to temperatures above 25°C for more than 48 hours loses potency and taste intensity. Check the reconstituted solution's appearance. It should be clear and colorless. Cloudiness, visible particles, or slow dissolution suggest the peptide has aggregated or degraded. If taste and appearance both seem off, do not use the vial for research. Contact your supplier for batch verification or replacement. High-purity hexarelin from Real Peptides delivers consistent bitterness across batches because each vial undergoes HPLC verification before shipping.

Use proper aseptic technique during reconstitution and handling. Inject bacteriostatic water slowly along the inside wall of the vial rather than directly onto the lyophilized powder. This prevents aerosolization. Swirl gently to dissolve; never shake vigorously. Wear gloves and avoid touching your face during handling. Work in a clean, enclosed space or laminar flow hood to prevent airborne peptide particles from contacting your mucosa. Once reconstituted, draw doses carefully using a fresh needle each time to avoid contaminating the vial. These steps eliminate nearly all accidental taste exposure while maintaining peptide integrity. The hexarelin oral taste is a handling artifact. Not an administration concern. When protocols are followed correctly.